259 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Acquired by Nemes Rush Group LLC

Nemes Rush Group LLC purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 259 shares of the company’s stock, valued at approximately $86,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. HighPoint Advisor Group LLC lifted its stake in shares of Medpace by 24.8% during the 4th quarter. HighPoint Advisor Group LLC now owns 795 shares of the company’s stock worth $261,000 after buying an additional 158 shares during the last quarter. Joseph Group Capital Management lifted its position in Medpace by 18.9% during the fourth quarter. Joseph Group Capital Management now owns 3,620 shares of the company’s stock worth $1,203,000 after acquiring an additional 575 shares during the last quarter. Orion Portfolio Solutions LLC boosted its holdings in shares of Medpace by 347.6% during the fourth quarter. Orion Portfolio Solutions LLC now owns 4,248 shares of the company’s stock worth $1,411,000 after acquiring an additional 3,299 shares during the period. New Age Alpha Advisors LLC acquired a new position in shares of Medpace in the fourth quarter valued at approximately $1,886,000. Finally, Norges Bank bought a new position in shares of Medpace during the fourth quarter worth approximately $69,859,000. 77.98% of the stock is owned by institutional investors.

Medpace Trading Up 4.5 %

Shares of Medpace stock opened at $311.23 on Thursday. The company has a market cap of $9.48 billion, a PE ratio of 24.64, a price-to-earnings-growth ratio of 3.81 and a beta of 1.45. The company has a 50 day moving average of $333.58 and a 200-day moving average of $338.33. Medpace Holdings, Inc. has a 1-year low of $289.01 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on MEDP shares. Leerink Partnrs raised Medpace to a “hold” rating in a report on Monday, March 24th. Robert W. Baird raised their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Finally, Leerink Partners assumed coverage on shares of Medpace in a research note on Monday, March 24th. They issued a “market perform” rating and a $330.00 price objective for the company. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $376.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.